Cancer arises from somatic mutations accumulating within a cell, disrupting crucial regulatory pathways controlling cell growth and division.  Understanding the precise genetic alterations driving individual cancers is paramount for personalized medicine.  Advances in next-generation sequencing (NGS) have facilitated comprehensive genomic profiling, identifying driver mutations and informing targeted therapies. However, several experimental challenges remain.  Firstly, the sheer complexity of cancer genomes, including the identification of low-frequency mutations and copy number variations, presents significant analytical hurdles.  Secondly, distinguishing driver mutations from passenger mutations remains a significant obstacle, hindering the accurate prediction of therapeutic response.  Furthermore,  the intratumoral heterogeneity of cancers – the presence of multiple genetically distinct cell populations within a single tumor – complicates treatment strategies, as a therapy effective against one subclone may not affect another.  Finally, translating genomic findings into clinically actionable insights requires robust preclinical models accurately reflecting the heterogeneity and complex interactions within the tumor microenvironment. Addressing these challenges through advanced bioinformatics, improved experimental models, and refined analytical techniques is crucial for realizing the full potential of personalized cancer medicine.